Biosion, Inc. Appoints CDA Thought Leader Dr. Rakesh Dixit to Advisory Board
NEWARK, Del., September 7, 2022 /PRNewswire/ — Biosion, Inc. (“Biosion”), a global biotechnology R&D company, today announced the appointment of Rakesh Dixit, Ph.D., DABT to its advisory board to advance antibody-drug conjugates (ADCs) for the treatment of solid tumor cancers in Biosion’s pipeline. Dr. Dixit is a highly accomplished leader and scientist, as evidenced by the most prestigious “Hundred Most Influential People in Pharmaceutical Industry” and “Longtime Contributions to the ADC Field” awards at the 2020 World ADC Awards , organized by the ADC Review Journal of Antibody Drug-Conjugates.
“We are delighted to welcome Dr. Dixit to the Biosion Advisory Board,” said Hugh DavisPh.D., Chief Operating Officer and President of Biosion UNITED STATESInc. “Dr. Dixit’s experience as a thought leader in ADC drug development and platform technologies will be invaluable to us as we advance our pipeline of next-generation biologics to treat resistant diseases. and residual solid tumours.”
“I am thrilled to work with the Biosion team to further their mission to deliver breakthrough treatments to patients around the world. ” said Rakesh Dixit, Ph.D., DABT. “Biosion’s SynTracer™ internalization platform is uniquely positioned to deliver monoclonal antibodies suitable for the purposes of ADC candidates, a next-generation approach to targeting cancer.
Dr. Dixit is an accomplished executive, inventor and scientist with more than 30 years of success with major biotech and pharmaceutical companies including Merck, Johnson & Johnson, Medimmune and AstraZeneca. During his more than 30-year career in the biopharmaceutical industry, he was a key contributor to the successful approval of biotherapeutic products, including five biologics (eg, antibodies, immunotoxins) and four small molecule pharmaceuticals . Dr. Dixit was honored in 2020 by the World ADC Forum with its most prestigious Long Standing Contributor to ADCs award. Dr. Dixit is currently President and CEO of Bionavigen, a biopharmaceutical company specializing in drug consulting and discovery for biological, cell and gene therapy and small molecule drug development. He is also Chairman and CSO of Regio Biosciences, an AstraZeneca spin-off company.
About Biosion, Inc.
Biosion is a global clinical-stage biotechnology company committed to developing antibody-based therapies to improve patient outcomes for the treatment of immune and oncology diseases. Founded in 2017, Biosion has built a pipeline of innovative biologics through its proprietary internally derived technologies, including the H³ antibody discovery platform, the SynTracer™ HT endocytosis platform and the Flexibody™ bispecific platform. Biosion’s flagship active ingredient, BSI-045B (anti-TSLP mAb), is currently in phase II for severe asthma and in phase I for atopic dermatitis. Biosion and its partners plan to advance the immuno-oncology and antibody-drug conjugate-based portfolio into clinical trials for oncology indications within the next year. Biosion is present in the United States, Australiaand China. To learn more about Biosion, visit www.biosion.com.
Mmedia and contact with investors